title: GIP and bariatric surgery.
abstract: Bariatric surgery is the most effective modality of achieving weight loss as well as the most effective treatment for type 2 diabetes mellitus (T2DM). Glucose-dependent insulinotropic polypeptide (GIP) is an incretin and is implicated in the pathogenesis of obesity and T2DM. Its role in weight loss and resolution of T2DM after bariatric surgery is very controversial. We have made an attempt to review the physiology of GIP and its role in weight loss and resolution of T2DM after bariatric surgery. We searched PubMed and included all relevant original articles (both human and animal) in the review. Whereas most human studies have shown a decrease in GIP post-malabsorptive bariatric surgery, the role of GIP in bariatric surgery done in animal experiments remains inconclusive.
authors.affiliation: Division of Metabolic, Endocrine and Minimally Invasive Surgery, Department of Surgery, Mount Sinai School of Medicine, New York, NY 10029, USA. Raghavendra.Rao@Mountsinai.org
authors.forename: Raghavendra S
authors.initials: RS
authors.lastname: Rao
authors.forename: Subhash
authors.initials: S
authors.lastname: Kini
mesh_terms: D000818:Animals; D050110:Bariatric Surgery; D003924:Diabetes Mellitus, Type 2 / Q000209:etiology* / Q000601:surgery*; D004195:Disease Models, Animal; D005749:Gastric Inhibitory Polypeptide / Q000502:physiology*; D006801:Humans; D009765:Obesity / Q000209:etiology* / Q000601:surgery*; D010446:Peptide Fragments / Q000502:physiology*; D015431:Weight Loss / Q000502:physiology*
chemical_list: D010446:Peptide Fragments; C101760:gastric inhibitory polypeptide (1-42); D005749:Gastric Inhibitory Polypeptide